Guillaume Pavlovic, PHENOMIN-ICS, will present a Webinar in collaboration with our partner Charles River
The topic: While the power CRISPR/Cas9* has to achieve targeted mutations in nearly any species is clear, what conclusions can we truly draw about its use in genome editing? Attend our webinar, where we’ll answer this question and more with topics including:
*CRISPR/Cas9 used under license to granted and pending US and international patents from ERS Genomics Limited.
Have a scheduling conflict? Sign up even if you can't make it; we'll share the recording after.